Navigation Links
Screening for β2-adrenergic receptor agonists using the pH-sensitive dye,CypHer5, and the IN Cell Analyzer 3000

High-throughput screening for potential targets is a major requirement in drug development and a key application is in the area of receptor activation, particularly G-protein coupled receptors (GPCRs) (1).

It is estimated that there are still 100–200 orphan GPCRs of potential therapeutic value requiring identification of natural or artificial ligands. The Sigma-RBI Library of Pharmacologically Active Compounds (LOPACTM) was used to demonstrate the capability of screening for potential agonists to the β 2-adrenergic receptor, a member of the Gs subfamily of GPCRs. This library consists of 640 well-characterized, pharmaceutically diverse compounds with known drug or drug-like activities. These compounds can be used to screen new drug targets for leads, guide secondary screening of large diverse libraries, characterize orphan receptors, and validate new high-throughput screening assays.

A clonal stable HEK293 cell line expressing the N-terminally VSV-G epitope-tagged β 2-adrenergic receptor was established using standard methods and assessed for receptor expression levels using radioligand binding studies (approximately 1.8 pmol/mg cell homogenate). The assay measuring β 2-adrenergic receptor internalization into acidic endosomal vesicles uses a red-excited pH-sensitive cyanine dye, CypHerTM5, which is effectively non-fluorescent at pH 7.4 and maximally fluorescent at pH 5.5 (2). An antibody to the N-terminal epitope-tag is labelled with CypHer5 and, on agonist stimulation, receptor internalization is detected as an increase in fluorescence in the cell. Dose response data and rank order potency were previously obtained for both agonist and antagonist treatment of β 2-adrenergic receptor-expressing cells (3).

Products used
CypHer5 labelled anti -VSV-G antibody, 250 mg PA45407

IN Cell Analyzer 3000 25-8010-11

Granularity Analysis Module 63-0048-97
(for IN Cell Analyzer 3000)

Other materials required
LOPAC (Sigma)

Culture medium:
MEM (Sigma) containing 10% (v/v) FBS, 200 µ g/ml G418, L-glutamine, non-essential amino acids

Assay medium: MEM (Sigma)

Agonist: Isoproterenol (Sigma)

Antagonist: Alprenolol (Sigma)

Fetal bovine serum (Gibco-BRL)

Geneticin G418 (Sigma)

Hoechst 33342 (Molecular Probes)

L-glutamine (Gibco-BRL)

Non-essential amino acids (Sigma)

Phosphate buffered saline (PBS) solution

Poly-D-lysine, 5 mg (Sigma)

96-well assay plate(Packard Viewplate)

The 640 pharmacologically active small organic compounds were provided in 96-well format, organized by receptor class/activity into eight plates (80 compounds per plate, 2 mg/well).
1. Adenosines/purinergics
2. Adrenergics/histaminergics
3. Cholinergics/ion channel modulators
4. Dopaminergics
5. Glutaminergics
6. Signal transduction agents/opioids
7. Serotonergics
8. Enzyme inhibitors/GABAergics

The β 2-adrenergic receptor agonist isoproteren ol (1 µ M) andantagonist alprenolol (1 µ M) were included as internal controls on each plate along with untreated cells for basal fluorescent levels.

Live-cell CypHer5 assay

1. Pre-coat 96-well plates with poly-D-lysine (recommended for HEK293 cells).

2. Seed cells at a density of 10–15 000 cells/well.

3. Incubate overnight at 37 ° C with 5% CO2.

4. Replace the culture medium with 100 µ l of fresh assay medium (MEM) containing 5 µ g/ml CypHer5 labelled anti-VSV-G antibody and 2.5 µ M Hoechst nuclear stain.

5. Add test compounds and controls to final assay concentrations of 40 µ g/ml and 1 µ M respectively.

6. Incubate at room temperature for 30 min.

7. Image on the IN Cell Analyzer 3000 with the following filter sets: 633 nm excitation and 695BP55 emission for CypHer5; 365 nm excitation and 450BP65 emission for Hoechst nuclear stain.

Quantitation of the receptor response can be achieved using the Granularity Analysis Module for the IN Cell Analyzer 3000, which identifies, counts, and analyzes grain-like structures within the cells. Figure 1 shows a scatter plot for β 2-adrenergic receptor expressing HEK cells, with and without isoproterenol stimulation. A signal:noise ratio of 10:1 and Z’ factor of 0.61 were obtained for this assay.

All eight LOPAC plates were imaged after incubation with control or test compounds. Granularity analysis results from the acquired images are shown in Figure 2 and summarized in Table 1.

Fourteen potential agonists were identified as showing an increase in CypHer5 fluorescence, indicating internalization of the β 2-adrenergic receptor. The majority (71 %) were from Plate 2: Adrenergics and histaminergics and included the β -adrenergic receptor agonists isoproterenol (three salts), epinephrine, salbutamol, and norepinephrine along with two α -adrenergic receptor agonists phenylephrine and iodoclonidine. Figure 3a shows receptor internalization responses for these agonists. The CypHer5 technology was effective in not only identifying the most active stimulants of β 2-adrenergic receptor internalization but also compounds with partial, low-affinity or non-specific action (3,6,7).

Putative agonists were also highlighted from three other plates. On Plate 4: Dopaminergics, the compound was identified as N-methyldopamine hydrochloride, also known as epinine hydrochloride or ibopamine. This is reported in the literature as a non-specific agonist for adrenergic receptors as well as a dopamine receptor agonist, with its affinity for dopaminergic > β 1 and β 2 adrenergic > α 1 and α 2 adrenergic receptors (4). On Plate 5: Glutaminergics, the compound was quisqualic acid, which has been shown to enhance norepinephrine release at excitatory amino acid receptors (5), suggesting it can lead indirectly to internalization of β 2-adrenergic receptors.

Figure 3b shows an example of the pattern of fluorescent grains obtained for the remaining two compounds on Plate 1: Adenosines/purinergics. They do not show the classic perinuclear clustering seen with internalization of β 2-adrenergic receptors into acidic endosomal vesicles and would appear to be false positives.

Agonist activation of cell surface receptors, which are used by the pharm aceutical industry as major drug targets, almost invariably results in the internalization of the receptor from the plasma membrane to the endosomal pathway within the cell. CypHer5 provides a generic approach to functional analysis and high-throughput primary and secondary screening of a broad range of cell surface receptors. CypHer5 and the IN Cell Analyzer 3000 are effective tools for the high-throughput screening of agonist-induced receptor internalization. They can also be used to identify the most active β 2-adrenergic receptor agonists present in a 640compound library along with compounds with potential agonist activity. The data presented support the use of CypHer5 in screening for new agonists of known receptors and potentially ligands of orphan receptors.

1. Milligan, G. Drug Discovery Today, 8 (13), 579–585 (2003).
2. Adie, E.J. et al. BioTechniques, 33, 1152 (2002).
3. Application Note: Pharmacological characterization of the β2-adrenergic
receptor with the pH sensitive dye, CypHer5, and IN Cell Analyzer 3000,
Amersham Biosciences, 18-1177-91, Edition AA (2003).
3. Pouleur et al. Clin. Cardiol., 18 (3 Suppl I), 117–21 (1995).
4. Pittaluga and Raiteri. J. Pharmacol. Exp. Ther,. 260 (1), 232–7 (1992).
5. Oakley RH et al. Journal of Biological Chemistry, 274 (45), 32248–32257 (1999).
6. Crider, J.Y. and Sharif, N.A. J. Ocul. Pharmacol. Ther., 18 (3), 221–30 (2002).

Note: The CypHer5 dye used in this application note was replaced in December 2003 by CypHer5E. This new pH-sensitive cyanine dye has the same mechanism of action as the previous compound but with the following enhanced features:

1. Higher extinction coeffic ient: can be used with cell lines that have lower receptor expression levels, enabling assays to be imaged on lower sensitivity instruments.

2. Increased sulfonation: Improved solubility, greater labeling efficiencies, and improved stability in solution.

More information comparing the performance of the two dyes can be found in the application note: The use of CypHer5E and the IN Cell Analyzer 1000 for live-cell receptor internalization studies (11-0008-22AA).

For further information, please contact your local sales office:

back to top


Page: All 1 2 3 4 5 6

Related biology technology :

1. Innovative Tissue Array Technology for High-Throughput Screening of Gene Expression
2. Screening of Beer-Spoilage Bacteria Using the LightCycler PCR Workflow System
3. LightCycler foodproof Beer Screening Kit
4. Development of a Multiplex Bead-Based Assay for Antibody Screening of a Nonhuman Primate Colony on the Bio-Plex System
5. Screening for potential beta 2-adrenergic receptor antagonists using CypHer5E and IN Cell Analyzer 1000
6. A Mix-and-Read Cell-Based Assay for Hybridoma Screening Using the FMAT 8100 HTS System
7. Simultaneous Screening of 23 Drugs of Abuse in Oral Fluid Using an LC/MS/MS Method
8. Rapid Screening of Amphetamine Drugs in Urine by Positive Ion Electrospray LC/MS/MS
9. Screening of Corticosteroids in Urine by Negative Atmospheric Pressure Chemical Ionization LC/MS/MS
10. Screening and classifying hazardous waste samples
11. The development of a CXCR2 chemokine receptorbinding assay using the LEADseeker Multimodality Imaging System
Post Your Comments:

(Date:1/19/2017)... , Jan. 19, 2017  Market Research Future has a ... Market for Liquid Biopsy is growing rapidly and expected to reach ... Market Highlights ... The Global Liquid Biopsy Market has been assessed as a swiftly ... figures and boom in the coming future. There has been a ...
(Date:1/19/2017)... Research and Markets ... the addition of the "Implantable Biomaterials Market Analysis ... report to their offering. Report Highlights: ... on current and future market trends to identify the investment opportunities ... base numbers Key market trends across the business segments, ...
(Date:1/19/2017)... Md. and GAITHERSBURG, Md. ... (NYSE MKT: PIP) and Altimmune, Inc., a privately-held ... signing of a definitive agreement for the merger ... Altimmune,s current investors include Novartis Venture Fund, HealthCap, ... will be a fully-integrated and diversified immunotherapeutics company ...
(Date:1/19/2017)... ... 18, 2017 , ... The American Medical Informatics Association (AMIA) ... Sharing Policy. Specifically, the nation’s leading informatics experts, said data sharing plans should ... AMIA recommended that NIH earmark funding for researchers to produce and execute data ...
Breaking Biology Technology:
(Date:12/22/2016)... 20, 2016  As part of its longstanding mission to ... genetics company, recently released its latest children,s book, titled ... focuses on the topics of inheritance and variation of traits ... taught in elementary school classrooms in the US. ... illustrator Ariana Killoran , whose previous book with 23andMe, ...
(Date:12/16/2016)... 2016   IdentyTechSolutions America LLC , a ... solutions and a cutting-edge manufacturer of software and ... offering seamless, integrated solutions that comprise IDT biometric ... solutions provide IdentyTech,s customers with combined physical identification ... crime and theft. "We are proud ...
(Date:12/15/2016)... 2016 ... Research and Markets has announced the addition of the ... The report forecasts the global military biometrics market to grow at ... report has been prepared based on an in-depth market analysis with inputs ... prospects over the coming years. The report also includes a discussion of ...
Breaking Biology News(10 mins):